Review of second-line therapy for multiple myeloma: Focus on lenalidomide

Current Opinion in Oncology

Volumn 24, Issue SUPPL. 2, 2012, Pages

  Mariz, José Mário ^a   Esteves, Graça Vasconcelos ^b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

lenalidomide; multiple myeloma; second line therapy

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMOXICILLIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ANEMIA; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; INFECTION; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

EID: 84855914414     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/01.cco.0000410243.84074.dc     Document Type: Review

References (59)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 2010; Current NCCN clinical practice guidelines on multiple myeloma.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-1873.
3. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21-33. (Pubitemid 36033957)
4. Harousseau JL, Dreyling M. Multiple myeloma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): ii55-ii57.
5. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109:3489-3495. (Pubitemid 46572539)
6. Myeloma Euronet. Multiple myeloma: frequently asked questions. 2010; 〈http://myeloma-euronet.org/en/multiple-myeloma/faq.php〉
7. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975; 50:29-40.
8. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8:773-783. (Pubitemid 47321600)
9. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23:1152-1157.
10. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25:1993-1999. (Pubitemid 46972782)
11. Schaapveld M, Visser O, Siesling S, et al. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010; 46:160-169.
12. Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010; 28:830-834.
13. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111:2521-2526.
14. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111:2516-2520.
15. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24:22-32.
16. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-2950.
17. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99:4525-4530. (Pubitemid 34627223)
18. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17:41-44. (Pubitemid 36175886)
19. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is antiangiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69:56-63. (Pubitemid 40410468)
20. Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006; 108:618-621. (Pubitemid 44061362)
21. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210-216.
22. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103:1787-1790. (Pubitemid 38268973)
23. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11:29-37.
24. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. NEngl J Med 2007; 357:2123-2132. (Pubitemid 350146107)
25. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357:2133-2142. (Pubitemid 350146108)
26. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17:1766-1771. (Pubitemid 44884050)
27. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113:4137-4143.
28. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108:3458-3464.
29. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of singleagent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114:772-778.
30. Chen C, Reece DE, Siegel D, et al. Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. Br J Haematol 2009; 146:164-170.
31. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137:268-269. (Pubitemid 46537629)
32. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112:4445-4451.
33. Stadtmauer EA,Weber DM, Niesvizky R, et al. Lenalidomide incombination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009; 82:426-432.
34. Dimopoulos MA, Palumbo A, Attal M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia 2011; 25:749-760.
35. San Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Longer duration of treatment and maintenance of best response with lenalidomide and dexamethasone prolongs overall survival in patients with relapsed or refractory multiple myeloma. Blood 2008; 112:Abstract 3702.
36. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114: 522-525.
37. Avet-Loiseau H, Soulier J, Fermand JP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamé thasone. Leukemia 2010; 24:623-628.
38. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009; 114:518-521.
39. Richardson P. Phase 1 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up. Blood 2010; 116:3049.
40. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116:679-686.
41. Schey SA, Morgan GJ, Ramasamy K, et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol 2010; 150:326-333.
42. Reece DE. Phase I-II trial of oral cyclophosphamide, prednisone, and lenalidomide (Revlimid) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. Blood 2010; 116:1260.
43. van de Donk. Br J Haematol 2009; 148:332-340.
44. Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox (Exjade1) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol 2010; 148:332-334.
45. Shah SR, Tran TM. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs 2007; 67:1869-1881. (Pubitemid 47347398)
46. Celgene Corporation. Revlimid (lenalidomide) prescribing information. 2010.
47. Ishak J, Dimopoulos MA, Weber D, et al. Declining rates of adverse events and dose modifications with lenalidomide in combination with dexamethasone. Blood 2008; 112:Abstract 3708.
48. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011; 11:38-43.
49. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100:3063-3067. (Pubitemid 35217050)
50. Celgene Corporation. Thalomid (thalidomide) prescribing information. 2010.
51. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111:3968-3977.
52. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment postperipheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21:2035-2042. (Pubitemid 47299979)
53. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050-4053. (Pubitemid 41775908)
54. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82:1179-1184. (Pubitemid 47502875)
55. Rajkumar SV. Phase II trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by ECOG. J Clin Oncol (ASCO) 2007; 25:LBA 8025.
56. Siegel DS, Jacobus S, Rajkumar SV, et al. Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial. Blood 2010; 116:38.
57. Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22:1282-1284. (Pubitemid 351833805)
58. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15:718-723.
59. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009; 114:5436-5443.